Mice Deficient in Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) are More Susceptible to Retinal Ischemic Injury In Vivo

Szabadfi, Krisztina; Atlasz, Tamás; Kiss, P.; Danyadi, B.; Tamás, Andrea; Helyes, Zsuzsanna; Hashimoto, Hitoshi; Shintani, Norihito; Baba, Akemichi; Tóth, Gábor; Gábriel, Róbert; Reglődi, Dóra

doi:10.1007/s12640-011-9254-y

Cited by 48 publications

(42 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pacap deficient mice displayed larger infarcted area in a model of focal cerebral ischemia and the extent of the ischemic retinal lesion was also increased [43]. there are similar findings in peripheral tissues in ischemic lesions.…”

Section: The Effect Of Endogenous Pacap In Ischemia/reperfusion-inducsupporting

confidence: 62%

The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

László¹,

Kiss²,

Horváth³

et al. 2014

Acta Biologica Hungarica

Self Cite

View full text Add to dashboard Cite

pituitary adenylate cyclase activating polypeptide (pacap) is a multifunctional neuropeptide occurring in the nervous system as well as in the peripheral organs. Beneficial action of PACAP has been shown in different pathological processes. The strong protective effects of the peptide are probably due to its complex modulatory actions in antiapoptotic, anti-inflammatory and antioxidant pathways. In the kidney, PACAP is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycinand cyclosporin-induced damages. Numerous studies have been published describing the protective effect of this peptide in renal ischemia/reperfusion. the present review focuses on the ischemia/reperfusioninduced kidney injury and gives a brief summary about the results published in this area.

show abstract

Section: The Effect Of Endogenous Pacap In Ischemia/reperfusion-inducsupporting

confidence: 62%

The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

László¹,

Kiss²,

Horváth³

et al. 2014

Acta Biologica Hungarica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Exogenous PACAP administration could partially protect against this retinal degeneration in the KO mice. These results clearly show that endogenous PACAP reacts as a stress-response peptide that is necessary for endogenous protection against different retinal insults [ 106 ].…”

Section: Studies In Pacap and Receptor Gene Modifi Ed Animalsmentioning

confidence: 61%

Protective Effects of PACAP in the Retina

Atlasz

Vaczy

Werling

et al. 2016

Current Topics in Neurotoxicity

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread neuropeptide that is well known for its general cytoprotective effects in different neuronal injuries, such as traumatic brain and spinal cord injury, models of neurodegenerative diseases, and cerebral ischemia. PACAP and its receptors also occur in the retina. In this review, we summarize the retinoprotective effects of PACAP. In vitro, PACAP is protective against glutamate, thapsigargin, anisomycin, oxidative stress, UV light, high glucose, infl ammation, and anoxia. Both the neural retina and the pigment epithelial cells can be protected by PACAP in various experimental paradigms. In vivo, the protective effects of intravitreal PACAP treatment have been shown in the following models in rats and mice: excitotoxic injury induced by glutamate, N -methyl-D -aspartate (NMDA) or kainate, ischemic injury induced by carotid artery ligation and high intraocular pressure, degeneration caused by UV-A light, optic nerve transection, and streptozotocin-induced diabetic retinopathy as well as retinopathy of prematurity. Molecular biological methods have revealed that PACAP activates anti-apoptotic, while inhibits pro-apoptotic signaling pathways, and it also stimulates an anti-infl ammatory environment in the retina. Altogether, PACAP is suggested to be a potential therapeutic retinoprotective agent in various retinal diseases.

show abstract

“…Ohtaki and coworkers showed that PACAP KO mice have increased infarct volume in a model of stroke [ 60 ] with increased edema formation [ 61 ]. Similar results were obtained in the retina: in bilateral carotid artery occlusioninduced retinal ischemia PACAP KO mice showed increased tissue damage [ 62 ]. In peripheral organ ischemia, it has been shown that PACAP KO mice react with increased tissue injury in ischemia-reperfusion-induced kidney lesion [ 27 , 63 ].…”

Section: Small Intestinal Ischemic Injury In Pacap Knockout (Ko) Micementioning

confidence: 67%

Protective Intestinal Effects of Pituitary Adenylate Cyclase Activating Polypeptide

Horváth

Illés

Heimesaat

et al. 2016

Current Topics in Neurotoxicity

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is an endogenous neuropeptide widely distributed throughout the body, including the gastrointestinal tract. Several effects have been described in human and animal intestines. Among others, PACAP infl uences secretion of intestinal glands, blood fl ow, and smooth muscle contraction. PACAP is a well-known cytoprotective peptide with strong anti-apoptotic, anti-infl ammatory, and antioxidant effects. The present review gives an overview of the intestinal protective actions of this neuropeptide. Exogenous PACAP treatment was protective in a rat model of small bowel autotransplantation. Radioimmunoassay (RIA) analysis of the intestinal tissue showed that endogenous PACAP levels gradually decreased with longer-lasting ischemic periods, prevented by PACAP addition. PACAP counteracted deleterious effects of ischemia on oxidative stress markers and cytokines. Another series of experiments investigated the role of endogenous PACAP in intestines in PACAP knockout (KO) mice. Warm ischemia-reperfusion injury and cold preservation models showed that the lack of PACAP caused a higher vulnerability against ischemic periods. Changes were more severe in PACAP KO mice at all examined time points. This fi nding was supported by increased levels of oxidative stress markers and decreased expression of antioxidant molecules. PACAP was proven to be protective not only in ischemic but also in infl ammatory bowel diseases. A recent study showed that PACAP treatment prolonged survival of Toxoplasma gondii infected mice suffering from acute ileitis and was able to reduce the ileal expression of proinfl ammatory cytokines. We completed the present review with recent clinical results obtained in patients suffering from infl ammatory bowel diseases. It was found that PACAP levels were altered depending on the activity, type of the disease, and antibiotic therapy, suggesting its probable role in infl ammatory events of the intestine.

show abstract

Mice Deficient in Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) are More Susceptible to Retinal Ischemic Injury In Vivo

Cited by 48 publications

References 81 publications

The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

Protective Effects of PACAP in the Retina

Protective Intestinal Effects of Pituitary Adenylate Cyclase Activating Polypeptide

Contact Info

Product

Resources

About